Table 2 Summary of study characteristics
Total studies included in systematic review | Ivermectin | Ivermectin and albendazole | All |
|---|---|---|---|
n (%) | n (%) | n (%) | |
8 (100) | 17 (100) | 25 (100) | |
Location | |||
 Africa | 1 (13) | 14 (82) | 15 (60) |
 South America | 3 (38) | 2 (12) | 5 (20) |
 South-East Asia | 0 | 1 (6) | 1 (4) |
 Western Pacific | 4 (50) | 0 | 4 (16) |
Study populationa | |||
 Children | 2 (25) | 6 (35) | 8 (32) |
 Adults | 1 (13) | 0 | 1 (4) |
 Community | 5 (63) | 11 (65) | 16 (64) |
Diagnostic method | |||
 Microscopy | 5 (63) | 15 (88) | 20 (80) |
 Molecular | 2 (25) | 1 (6) | 3 (12) |
 Serology | 1 (13) | 1 (6) | 2 (8) |
Primary disease target of preventive chemotherapyb | |||
 Lymphatic filariasis | 1 (13) | 14 (82) | 15 (60) |
 Oesophagostomiasis | 0 | 2 (12) | 2 (8) |
 Onchocerciasis | 3 (38) | 3 (18) | 6 (24) |
 Parasitic skin diseases or scabies | 4 (50) | 0 | 4 (16) |
 Schistosomiasis | 0 | 5 (29) | 5 (20) |
 Soil-transmitted helminths | 0 | 9 (53) | 9 (36) |
Additional drugs used in preventive chemotherapy | |||
 Azithromycin | 1 (13) | 0 | 1 (4) |
 Diethylcarbamazine citrate | 1 (13) | 1 (6) | 2 (8) |
 Mebendazole | 0 | 1 (6) | 1 (4) |
 Praziquantel | 0 | 5 (29) | 5 (20) |
Ivermectin administration strategy | |||
 School-based only | 0 | 0 | 0 |
 Mass drug administration only | 8 (100) | 17 (100) | 25 (100) |
Albendazole administration strategy | |||
 School-based only | NA | 0 | 0 |
 Mass drug administration only | NA | 13 (76) | 13 (52) |
 Both | NA | 4 (24) | 4 (16) |
Number of rounds | |||
 1 | 5 (63) | 5 (29) | 10 (40) |
 2–5 | 2 (25) | 10 (59) | 12 (48) |
 > 5 | 1 (13) | 2 (12) | 3 (12) |
Follow-up time from last round | |||
 ≤ 6 months | 3 (38) | 3 (18) | 6 (24) |
 > 6–12 months | 3 (38) | 7 (42) | 10 (40) |
 > 12–24 months | 2 (25) | 6 (35) | 8 (32) |
 > 24 months | 0 | 1 (6) | 1 (12) |
Intervention coverage | |||
 < 75% | 0 | 8 (47) | 8 (32) |
 ≥ 75% | 7 (88) | 6 (35) | 13 (52) |
 Not reported | 1 (13) | 3 (18) | 4 (16) |